Compare Sanofi SA (SNY) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Victoria's Secret & Co — how do they compare? Sanofi SA trades at $42.95 (market cap $103.41B), while Victoria's Secret & Co trades at $76 (market cap $6.04B). The key difference: Sanofi SA is far larger — about 17.1× Victoria's Secret & Co's market cap, and Sanofi SA pays a 5.65% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals.
| SNY | VSXY | |
|---|---|---|
Market Cap | $103.41B | $6.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $99.97 |
52-Week Low | $41.33 | $25.56 |
Enterprise Value | $123.44B | $8.42B |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Victoria's Secret (VSXY) trades at $78.47, up 3.85% over 24 hours, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability metrics, including a 45.27% ROE and 39.57% gross margin, but faces revenue stagnation and negative net cash flow trends. Recent news highlights PINK brand growth and Q2 2026 earnings surpassing estimates, though the stock fell due to sales concerns.
The outlook is mixed: analyst consensus is bullish with a $94.86 price target, but technical weakness and competitive pressures pose risks. Earnings momentum and cost management are key drivers for upside, while investor sentiment remains cautious amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
